Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary extracted from

  • Takeuchi, M.; Kimura, S.; Kuroda, J.; Ashihara, E.; Kawatani, M.; Osada, H.; Umezawa, K.; Yasui, E.; Imoto, M.; Tsuruo, T.; Yokota, A.; Tanaka, R.; Nagao, R.; Nakahata, T.; Fujiyama, Y.; Maekawa, T.
    Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment (2010), Cell Death Differ., 17, 1211-1220.
    View publication on PubMed

Application

EC Number Application Comment Organism
4.4.1.5 medicine Glo-I is a molecular target for treatment of Bcr-Abl+ leukemias and, in particular, Abl TKI-resistant quiescent Bcr-Abl+ leukemic cells that have acquired stem-like characteristics in the process of adapting to a hypoxic environment Homo sapiens

Organism

EC Number Organism UniProt Comment Textmining
4.4.1.5 Homo sapiens
-
-
-

Source Tissue

EC Number Source Tissue Comment Organism Textmining
4.4.1.5 leukemic stem cell Bcr-Abl+ leukemic stem cell Homo sapiens
-

Substrates and Products (Substrate)

EC Number Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
4.4.1.5 methylglyoxal + glutathione
-
Homo sapiens (R)-S-lactoylglutathione
-
?

Synonyms

EC Number Synonyms Comment Organism
4.4.1.5 GLO-I
-
Homo sapiens
4.4.1.5 glyoxalase-I
-
Homo sapiens

Cofactor

EC Number Cofactor Comment Organism Structure
4.4.1.5 glutathione
-
Homo sapiens

Expression

EC Number Organism Comment Expression
4.4.1.5 Homo sapiens compared with the respective parental cells, hypoxia adapted-Bcr-Abl+ cells have higher levels of protein and higher enzyme activity of glyoxalase-I. High Glo-I expression is sustained in hypoxia adapted-chronic myeloid leukemia cells after 6 months in normoxia up